Erik Thunnissen

List of PR Articles by Year in descending order

Source: //exaly.com/author-pdf/170142/publications.pdf

Version: 2025-02-01

106 PR articles	14,754 PR citations	33822 46 PR h-index	19203 105 g-index
120 documents	20397 doc citations	27159 53 h-index	21306 citing authors

#	Article	IF	PR Citations
1	Prognostic value of proliferation, PD-L1 and nuclear size in patients with superior sulcus tumours treated with chemoradiotherapy and surgery. Journal of Clinical Pathology, 2023, 76, 111-115.	2.0	2
2	Diagnosis of atypical carcinoid can be made on biopsiesâ€‰>â€‰4 mm2 and is accurate. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 587-593.	3.0	10
3	The impact of a pathologistâ€™s personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer. Lung Cancer, 2022, 166, 143-149.	2.7	28
4	The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer, 2021, 154, 161-175.	2.7	178
5	RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 798-806.	2.2	38
6	Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2021, 16, 990-1002.	2.2	59
7	<scp>COVID</scp>â€19: Histopathological correlates of imaging patterns on chest <scp>computed tomography</scp>. Respirology, 2021, 26, 869-877.	4.1	28
8	Polarization-sensitive optical coherence tomography in end-stage lung diseases: an ex vivo pilot study. Biomedical Optics Express, 2021, 12, 6796.	2.9	9
9	Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization. Archives of Pathology and Laboratory Medicine, 2020, 144, 735-741.	2.5	30
10	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	2.2	281
11	External quality assessment demonstrates that PDâ€L1 22C3 and SP263 assays are systematically different. Journal of Pathology: Clinical Research, 2020, 6, 138-145.	3.4	31
12	Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer. Journal of Clinical Pathology, 2020, 73, 423-430.	2.0	17
13	Morphologic Logic: â€œFiligreeâ€•and â€œClassicalâ€•Micropapillary Pattern Are Orientation-Dependent Views of the Same Lesion. Journal of Thoracic Oncology, 2020, 15, e120-e121.	2.2	6
14	Lung cancer biomarker testing: perspective from Europe. Translational Lung Cancer Research, 2020, 9, 887-897.	2.1	29
15	RE: Spread Through Air Spaces (STAS) is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. Journal of Thoracic Oncology, 2020, 15, e116-e117.	2.2	3
16	Pathologists should probably forget about kappa. Percent agreement, diagnostic specificity and related metrics provide more clinically applicable measures of interobserver variability. Annals of Diagnostic Pathology, 2020, 47, 151561.	1.2	28
17	Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Nonâ€“Small-Cell Lung Cancer. Journal of Molecular Diagnostics, 2020, 22, 1438-1452.	2.6	9
18	Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples. BMC Cancer, 2020, 20, .	3.1	3

#	Article	IF	PR Citations
19	Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy. British Journal of Cancer, 2020, 123, 392-402.	5.7	42
20	Tumor Atelectasis Gives Rise to a Solid Appearance in Pulmonary Adenocarcinomas on High-Resolution Computed Tomography. JTO Clinical and Research Reports, 2020, 1, 100018.	1.0	2
21	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	2.2	254
22	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1599-1610.	2.2	455
23	Quantification of PD-L1 Expression with ¹⁸F-BMS-986192 PET/CT in Patients with Advanced-Stage Nonâ€“Small Cell Lung Cancer. Journal of Nuclear Medicine, 2020, 61, 1455-1460.	5.6	71
24	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	2.2	372
25	Influence of preanalytical variables on performance of delta-like protein 3 (DLL3) predictive immunohistochemistry. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 478, 293-300.	3.0	2
26	In Reply. Archives of Pathology and Laboratory Medicine, 2019, 143, 909-910.	2.5	1
27	Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 191-199.	3.0	54
28	Clonality analysis of pulmonary tumors by genome-wide copy number profiling. PLoS ONE, 2019, 14, e0223827.	2.4	12
29	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Lung Cancer, 2019, 131, 95-103.	2.7	45
30	Gross handling of pulmonary resection specimen: maintaining the 3-dimensional orientation. Journal of Thoracic Disease, 2019, 11, S37-S44.	1.3	22
31	A Population-Based Study of Outcomes in Surgically Resected T3N0 Nonâ€“Small Cell Lung Cancer in The Netherlands, Defined Using TNM-7 and TNM-8; Justification of Changes and an Argument to Incorporate Histology in the Staging Algorithm. Journal of Thoracic Oncology, 2019, 14, 459-467.	2.2	18
32	Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction. Journal of Proteomics, 2019, 196, 106-119.	2.4	28
33	How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Nonâ€“Small Cell Lung Cancer. Archives of Pathology and Laboratory Medicine, 2019, 143, 11-12.	2.5	18
34	Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens?. Histopathology, 2019, 74, 555-566.	3.7	42
35	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage Iâ€“III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. Modern Pathology, 2019, 33, 792-801.	4.9	31
36	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Archives of Pathology and Laboratory Medicine, 2018, 142, 321-346.	2.5	728

#	Article	IF	PR Citations
37	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. Journal of Thoracic Oncology, 2018, 13, 205-217.	2.2	47
38	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2018, 13, 413-425.	2.2	79
39	Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. Clinical Cancer Research, 2018, 24, 1337-1343.	6.9	84
40	Rapid On-Site Evaluation of Endobronchial Ultrasoundâ€“Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2018, 142, 253-262.	2.5	155
41	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2018, 142, 408-419.	2.5	74
42	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 1569-1576.	2.2	228
43	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. Journal of Thoracic Oncology, 2018, 13, 1302-1311.	2.2	708
44	Pulmonary loose tumor tissue fragments and spread through air spaces (STAS): Invasive pattern or artifact? A critical review. Lung Cancer, 2018, 123, 107-111.	2.7	41
45	Comprehensive Hybrid Captureâ€“Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative by FISH. Journal of Thoracic Oncology, 2017, 12, e22-e24.	2.2	8
46	DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2â€…years. Journal of Clinical Pathology, 2017, 70, 250-254.	2.0	25
47	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. Journal of Thoracic Oncology, 2017, 12, 334-346.	2.2	130
48	PD-L1 IHC in NSCLC with a global and methodological perspective. Lung Cancer, 2017, 113, 102-105.	2.7	41
49	Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer, 2017, 111, 143-149.	2.7	71
50	Reply to Letter â€œThe Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases.â€• Journal of Thoracic Oncology, 2017, 12, e70-e71.	2.2	5
51	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens. European Respiratory Review, 2017, 26, 170007.	8.7	96
52	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget, 2016, 7, 1066-1075.	1.7	194
53	Ex Vivo Artifacts and Histopathologic Pitfalls in the Lung. Archives of Pathology and Laboratory Medicine, 2016, 140, 212-220.	2.5	91
54	Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 489-503.	3.0	213

#	Article	IF	PR Citations
55	Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC. EJNMMI Research, 2016, 6, .	2.7	30
56	A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors. Journal of Thoracic Oncology, 2016, 11, 593-602.	2.2	13
57	Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax, 2016, 71, 177-184.	5.8	180
58	Clinical features of large cell neuroendocrine carcinoma: a population-based overview. European Respiratory Journal, 2016, 47, 615-624.	12.1	115
59	Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 470, 5-20.	3.0	97
60	Detecting Resistance in Egfr -Mutated Non-Small-Cell Lung Cancer After Clonal Selection Through Targeted Therapy. Personalized Medicine, 2015, 12, 63-66.	1.4	2
61	Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?. Lung Cancer, 2015, 89, 19-26.	2.7	7
62	Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. Lung Cancer, 2015, 89, 255-261.	2.7	127
63	Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53.	38.7	2,103
64	Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1483-1489.	12.2	44
65	Diagnostic challenges in survivors of early stage lung cancer. Lung Cancer, 2015, 90, 212-216.	2.7	3
66	Towards a close computed tomography monitoring approach for screen detected subsolid pulmonary nodules?. European Respiratory Journal, 2015, 45, 765-773.	12.1	116
67	Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?. Familial Cancer, 2015, 15, 297-300.	1.5	5
68	The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization. PLoS ONE, 2014, 9, e112159.	2.4	29
69	Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis. Journal of Clinical Pathology, 2014, 67, 707-711.	2.0	63
70	Guidance for laboratories performing molecular pathology for cancer patients. Journal of Clinical Pathology, 2014, 67, 923-931.	2.0	188
71	Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study. Journal of Thoracic Oncology, 2014, 9, 1354-1362.	2.2	38
72	Prognostic and predictive biomarkers in lung cancer. A review. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 347-358.	3.0	80

#	Article	IF	PR Citations
73	Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cellular Oncology (Dordrecht), 2014, 37, 353-361.	4.2	45
74	Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. Lancet Oncology, The, 2014, 15, 1342-1350.	26.0	348
75	Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 547-556.	3.0	21
76	EGFR mutation analysis in sputum of lung cancer patients: A multitechnique study. Lung Cancer, 2013, 82, 38-43.	2.7	35
77	Characteristics of Lung Cancers Detected by Computer Tomography Screening in the Randomized NELSON Trial. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 848-854.	12.2	249
78	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Archives of Pathology and Laboratory Medicine, 2013, 137, 828-860.	2.5	427
79	Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. European Respiratory Journal, 2013, 42, 1659-1667.	12.1	219
80	Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Archives of Pathology and Laboratory Medicine, 2013, 137, 668-684.	2.5	390
81	Reproducibility of Immunohistochemical Scoring for Epidermal Growth Factor Receptor Expression in Nonâ€“Small Cell Lung Cancer: Round Robin Test. Archives of Pathology and Laboratory Medicine, 2013, 137, 1255-1261.	2.5	26
82	Tumor size does not predict pathological complete response rates after pre-operative chemoradiotherapy for non-small cell lung cancer. Acta OncolÃ³gica, 2013, 52, 676-678.	1.8	2
83	In Compressed Lung Tissue Microscopic Sections of Adenocarcinoma In Situ May Mimic Papillary Adenocarcinoma. Archives of Pathology and Laboratory Medicine, 2013, 137, 1792-1797.	2.5	25
84	Diagnosis of Lung Adenocarcinoma in Resected Specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Archives of Pathology and Laboratory Medicine, 2013, 137, 685-705.	2.5	159
85	CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids. Clinical Cancer Research, 2013, 19, 2197-2207.	6.9	95
86	A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Nonâ€“Small Cell Lung Cancer with a KRAS Mutation. Clinical Cancer Research, 2013, 19, 743-751.	6.9	77
87	Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status. Clinical Cancer Research, 2013, 19, 183-193.	6.9	120
88	KRAS Mutations in Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value. Journal of Thoracic Oncology, 2013, 8, 1190-1195.	2.2	43
89	Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3â€²-Deoxy-3â€²-[18F]fluorothymidine Positron Emission Tomography. PLoS ONE, 2013, 8, e63705.	2.4	20
90	Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer. Journal of Clinical Pathology, 2012, 65, 541-545.	2.0	20

#	Article	IF	PR Citations
91	An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?. Journal of Thoracic Oncology, 2012, 7, e3-e5.	2.2	3
92	Negative NKX2-1 (TTF-1) as Temporary Surrogate Marker for Treatment Selection During EGFR-Mutation Analysis in Patients with Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1522-1527.	2.2	26
93	Applying Biomarker Testing to Clinical Practice in Lung Cancer. Lung Cancer Management, 2012, 1, 145-154.	0.6	0
94	KRAS and BRAF Mutation Analysis in Routine Molecular Diagnostics. Journal of Molecular Diagnostics, 2012, 14, 247-255.	2.6	53
95	Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Modern Pathology, 2012, 25, 1574-1583.	4.9	231
96	EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 245-257.	3.0	204
97	Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 629-638.	3.0	32
98	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer, 2012, 76, 1-18.	2.7	223
99	Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 462, 27-37.	3.0	73
100	A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation. Familial Cancer, 2012, 12, 373-379.	1.5	21
101	Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin. Clinical Cancer Research, 2011, 17, 2581-2590.	6.9	96
102	EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. Journal of Clinical Pathology, 2011, 64, 884-892.	2.0	32
103	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 244-285.	2.2	4,574
104	Bronchioloalveolar Adenocarcinoma and Pulmonary Langerhans Cell Histiocytosis in a Patient With MUTYH-Associated Polyposis. Journal of Clinical Oncology, 2011, 29, e188-e190.	21.6	6
105	Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer. Science Translational Medicine, 2010, 2, .	12.7	790
106	Management of Lung Nodules Detected by Volume CT Scanning. New England Journal of Medicine, 2009, 361, 2221-2229.	43.7	795